Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Tolerability, and Safety Study of DFN-15

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A history of episodic migraine, who experience 2 to 8 migraine attacks per month for at least the past 12 months, with no more than 14 headache days per month, and with 48 hours of headache-free time between migraine attacks.~2. Patients who have migraine with or without aura with onset before age 50 years~3. Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity scale without treatment.~4. Subjects who are willing and able to:~   1. Evaluate and record pain, migraine symptoms, and study drug effectiveness information in real-time using a subject eDiary for the duration of the study;~  2. Record each instance of the use of study drug and rescue medication in real-time using a subject eDiary for the duration of the study;~  3. Comply with all other study procedures and scheduling requirements.~Exclusion Criteria:~1. Minors, even if they are in the specified study age range~2. Medication overuse:~   1. Opioids greater than or equal to 10 days during the 90 days prior to screening~  2. Combination medications (e.g., Fiorinal®) greater than or equal to 10 days during the 90 days prior to screening (applies only if includes opioid and/or barbiturate)~  3. Nonsteroidal Anti-inflammatory Drugs or other simple medications greater than 14 days a month during the 90 days prior to screening~  4. Triptans or ergots greater than or equal to 10 days a month during the 90 days prior to screening~3. Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to screening. (If treated for cosmetic reasons, subjects may be included).~4. Current treatment with antipsychotics or use of antipsychotics within 30 days prior to randomization.~5. Patients who have received treatment with an investigational drug or device within 30 days of randomization, or participated in a central nervous system clinical trial within 2 months prior to randomization~6. Patients with positive screening test for human immunodeficiency virus \[HIV\], positive hepatitis B surface antigen (HBsAg), or positive hepatitis C virus \[HCV\] antibody~7. Subjects who are employees or immediate relatives of the employees of the Sponsor, any of its affiliates or partners, or of the clinical research study site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DFN-15 Active (Type: EXPERIMENTAL): DFN-15 Active
- DFN-15 Placebo (Type: PLACEBO_COMPARATOR): DFN-15 Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).